DRMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dermata Therapeutics Inc (DRMA) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock shows weak financial performance, no significant positive catalysts, and lacks strong technical or trading signals to justify immediate investment. Holding off on this stock is recommended until better entry points or stronger fundamentals emerge.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 61.998, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), signaling a downward trend. The stock is trading near its resistance levels (R1: 1.372, R2: 1.424), which may limit further upward movement.
NULL identified. No recent news or significant insider/hedge fund activity. AI Stock Picker and SwingMax signals are absent.
Weak financial performance with a significant drop in net income (-40.91% YoY) and EPS (-91.99% YoY). Analysts have lowered the price target from $10 to $4 due to share dilution and wider GAAP losses. No recent congress trading data or news to support positive sentiment.
In Q4 2025, the company reported no revenue growth (0% YoY), a significant drop in net income to -$1,861,888 (-40.91% YoY), and a sharp decline in EPS to -1.65 (-91.99% YoY). Gross margin remains at 0%. Overall, the financials indicate poor performance and no growth trends.
Maxim has maintained a Buy rating but significantly lowered the price target from $10 to $4, citing share dilution and wider GAAP losses. This reflects a cautious outlook despite the Buy rating.
